Analysis of Beyfortus® (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention
- Hélène Banoun
Access Resources
About
This review article analyzes the Beyfortus® (Nirsevimab) Immunization Campaign's effectiveness in preventing RSV infections. Nirsevimab shows promise in reducing hospitalizations due to RSV with its strong binding to RSV F protein and extended lifespan. However, there are concerns about potential biases in studies and risks of antibody-dependent enhancement (ADE) leading to worsened infections. The incomplete assessment of ADE risk and the high cost of nirsevimab raise questions about the cost-effectiveness of mass immunization campaigns. The article highlights the need for further exploration of nirsevimab's effector functions and pharmacokinetics to ensure its safety and efficacy in preventing respiratory infections.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.